We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biophan Technologies has announced the development of a new, ultra-small model
of the implantable and wearable, highly precise ceramic SQUIGGLE motor that's
half the size of previous models, with significant improvements in precision
and electrical efficiency compared to electromagnetic motors.
MIV Therapeutics, a developer of next-generation biocompatible coatings and
drug delivery technologies, has filed two new patent applications that will
enable the development and manufacture of an advanced new class of drug-eluting
coatings capable of delivering multiple medicines from a cardiovascular stent
or other implanted medical devices.
Utah Medical Products continues its efforts to discover the basis for a lawsuit
filed eight months ago by the FDA in the U.S. District Court in Salt Lake City,
alleging failure to comply with the FDA Quality System Regulation (QSR).
Novare Surgical Systems announced that it has received clearance from the FDA
to market its family of EndoLink surgical instruments, single-use hand-held
instruments that incorporate six degrees of articulating freedom.
Boston Scientific announced that it has received CE Mark for three large vessel
sizes (4.0 mm, 4.5 mm and 5.0 mm) of its Taxus Express2 paclitaxel-eluting coronary
stent system in Europe and other international markets.
A federal appeals court rejected a claim by two lawyers who argued that the
federal Medicare program was defrauded by a company that made defective wires
for heart pacemakers.
St. Jude Medical announced it has completed the acquisition of the business
of Velocimed, a privately owned company that develops, manufactures and markets
specialty interventional cardiology devices.
Neoprobe, a diversified developer of innovative oncology diagnostic and treatment
products and cardiovascular surgical and diagnostic products, announced that
it has completed a license agreement for U.S. Patent Nos. 6,418,338 and 6,760,612
B2 issued July 9, 2002 and July 6, 2004, respectively.
Tucson, Ariz.-based ImaRx Therapeutics announced the beginning of treatment
for the first patient in a new Phase II clinical trial for its stroke treatment.